Krystal Biotech Announces Second Quarter 2022 Financial Results and Reports Updates on Operational Progress
08. August 2022 07:00 ET
|
Krystal Biotech, Inc.
Biologics License Application for B-VEC filed with the FDA on June 22, 2022FDA accepts IND on KB407 for the treatment of Cystic FibrosisStrong balance sheet, closing the quarter with $438.5 million in...
Krystal Biotech Announces FDA Acceptance of KB407 IND Application for Cystic Fibrosis Clinical Trial
01. August 2022 18:39 ET
|
Krystal Biotech, Inc.
KB407 is an investigational, redosable gene therapy candidate designed to treat all patients with cystic fibrosis regardless of the underlying genetic mutation PITTSBURGH, Aug. 01, 2022 (GLOBE...
Krystal Biotech Receives FDA Acceptance of KB407 IND Application for Cystic Fibrosis Clinical Trial
01. August 2022 07:00 ET
|
Krystal Biotech, Inc.
KB407 is an investigational, redosable gene therapy candidate designed to treat all patients with cystic fibrosis regardless of the underlying genetic mutation PITTSBURGH, Aug. 01, 2022 (GLOBE...
Krystal Biotech to Present at William Blair Biotech Focus Conference 2022
06. Juli 2022 07:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, July 06, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the...
Krystal Biotech Submits Biologics License Application to U.S. FDA Seeking Approval of B-VEC for the Treatment of Patients with Dystrophic Epidermolysis Bullosa
22. Juni 2022 07:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, June 22, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today the submission of a Biologics License...
Krystal Biotech to Present at Goldman Sachs 43rd Annual Global Healthcare Conference
07. Juni 2022 07:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, June 07, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the...
Krystal Biotech to Present Additional Data on B-VEC from the GEM-3 Phase 3 Study at the Society for Investigative Dermatology Annual Meeting
19. Mai 2022 19:30 ET
|
Krystal Biotech, Inc.
PITTSBURGH, May 19, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, is pleased to present new data entitled “GEM-3: phase 3...
Krystal Biotech Announces First Quarter 2022 Financial Results and Reports Updates on Operational Progress
09. Mai 2022 16:15 ET
|
Krystal Biotech, Inc.
Biologics License Application for B-VEC remains on track to file in the US in 2Q 2022 and Marketing Authorization in the EU on track to file in 2H 2022FDA allows dosing at a patient’s home in the Open...
Krystal Biotech to Participate in Bank of America Merrill Lynch Global Healthcare Conference
03. Mai 2022 07:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, May 03, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that Krish S. Krishnan, Chairman and Chief...
Krystal Biotech Announces Home Dosing in B-VEC Open Label Extension Study
11. April 2022 07:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, April 11, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies, today announced that it plans to offer patients with...